TPC Marketing Research reports on AI drug discovery business strategies

TPC Marketing Research Co., Ltd. has released a report regarding business strategies in AI-driven drug discovery. The research highlights how AI is being utilized to address the high costs and low success rates associated with traditional new drug development.

As AI and machine learning technologies advance, their application is expanding across the entire drug discovery process, including target identification, molecular design, and clinical development. The emergence of generative AI and multimodal AI is enabling the analysis of large-scale biological and chemical datasets.

The report identifies three primary strategic actors: pharmaceutical companies implementing AI in R&D, AI ventures developing specialized platforms, and Big Tech companies providing the necessary computational infrastructure, such as cloud services and GPUs. The industry is currently transitioning from using AI primarily for research support to a phase focused on the practical commercialization and development of actual drug candidates.